Role of steroid hormones and growth factors in breast cancer

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 10, 2002, Pages 969-974

  Lai, Leslie C ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Breast cancer; Carotenoids; Growth factors; Oestrogen; Retinoic acid; Tumours suppressor genes

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CAROTENOID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; GROWTH FACTOR; MITOGENIC AGENT; ONCOPROTEIN; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN P53; RETINOIC ACID; STEROID HORMONE; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GROWTH PROMOTOR; STEROID;

BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INCIDENCE; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GROWTH INHIBITION; HORMONAL CARCINOGENESIS; HORMONAL THERAPY; HUMAN; INHERITANCE; ONCOGENE C ERB; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; BREAST TUMOR; CELL DIVISION; DRUG EFFECT; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

MINK CELL FOCUS-FORMING VIRUS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; FEMALE; GROWTH SUBSTANCES; HUMANS; MUTATION; RECEPTORS, ESTROGEN; STEROIDS;

EID: 0036430731     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.170     Document Type: Review

References (89)

1. Kelsey JL, Horn-Ross PL. Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 1993; 15:7-16.
2. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2:133-40.
3. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77:2318-24.
4. James VHT, Reed MJ. Steroid hormones and human cancer. In: Iacobelli S, King RJB, Lindner HR, Lippman ME, editors. Hormones and cancer. New York: Raven Press, 1980:471-87.
5. Santner SJ, Feil PD, Santen RJ. In situ estrogen production via estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 1984; 59:29-33.
6. Dawson MI, Chao WR, Hobbs PD, Zhang XK. Effects of trans-retinoic acid, 9-cis-retinoic acid, 1alpha,25-(dihydroxy)vitamin D3 and a novel apoptosis-inducing retinoid on breast cancer and endothelial cell growth. Cancer Lett 1998; 133:1-8.
7. Fontana JA, Burrows MA, Cooper BN, Miranda D. Retinoid modulation of estradiol-stimulated growth and of protein synthesis and secretion in human breast carcinoma cells. Cancer Res 1990; 50:1997-2002.
8. Narisawa T, Fukuara Y, Hasebe M, Ito M, Aizawa R, Murakoshi M, et al. Inhibitory effects of natural carotenoids, α-carotene, β-carotene, lycopene and lutein on colonic aberrant crypt foci formation in rats. Cancer Lett 1996; 107:137-42.
9. Murakoshi M, Nishino H, Satomi Y, Takayasu J, Hasegawa T, Tokuda H, et al. Potent preventive action of alpha-carotene against carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by alpha-carotene than beta-carotene. Cancer Res 1992; 53:6583-7.
10. Goustin AS, Leof EB, Shipley GD, Moses HL. Growth factors and cancer. Cancer Res 1986; 46:1015-29.
11. Dickson RB, Lippman ME. Growth regulation of normal and malignant breast epithelium. In: Bland KI, Copeland EM, editors. The breast. Philadelphia: WB Saunders, 1991:363.
12. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type β transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 1985; 82:119-23.
13. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5:953-62.
14. Bargmann CL, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319:226-30.
15. Begg L, Kuller, LH, Gutai JP, Caggiula AG, Wolmark N, Watson CG. Endogenous sex hormone levels and breast cancer risk. Genet Epidemiol 1987; 4:233-47.
16. Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994; 86:1403-8.
17. Yuan JM, Yu MC, Ross RK, Gao YT, Henderson BE. Risk factors for breast cancer in Chinese women in Shanghai. Cancer Res 1988; 48:1949-53.
18. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy; collaborative re-analysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350:1047-59.
19. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002; 3:303-11.
20. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, et al. Age at first birth and breast cancer risk. Bull World Health Organ 1970; 43:209-21.
21. Pujol P, Galtier-Dereure F, Bringer J. Obesity and breast cancer risk. Hum Reprod 1997; 12:116-25.
22. Land CE. Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer. J Am Med Assoc 1995; 274:402-7.
23. Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S. Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiat Res 1994; 138:915-23.
24. Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol 1998; 16:338-47.
25. Bowlin SJ, Leske MC, Varma A, Nasca P, Weinstein A, Caplan L. Breast cancer risk and alcohol consumption: results from a large case-control study. Int J Epidemiol 1997; 26:915-23.
26. Nagata C, Kabuto M, Takatsuka N, Shimizu H. Associations of alcohol, height and reproductive factors with serum hormone concentrations in postmenopausal Japanese women. Steroid hormones in Japanese postmenopausal women. Breast Cancer Res Treat 1997; 44:235-41.
27. Boyd NF, Martin LJ, Noffel M, Lockwood GA, Trichler DL. A meta-analysis of studies of dietary fat and breast cancer risk. Br J Cancer 1993; 68:627-36.
28. Wynder EL, Cohen LA, Muscat JE, Winters B, Dwyer JT, Blackburn G. Breast cancer: weighing the evidence for a promoting role of dietary fat. J Natl Cancer Inst 1997; 89:766-75.
29. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-9.
30. Struewing JP, Tarone RE, Brody LC, Li FP, Boice JD Jr. BRCA1 mutations in young women with breast cancer. Lancet 1996; 347:1493.
31. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52:678-701.
32. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Human Genet 1995; 56:265-71.
33. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 1998; 19:254-6.
34. Hsu LC, White RL. BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci USA 1998; 95:12983-8.
35. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998; 281:1009-12.
36. Shao N, Chai YL, Shyam E, Reddy P, Rao VN. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 1996; 13:1-7.
37. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265:2088-90.
38. Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Human Genet 1997; 61:120-8.
39. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Human Genet 1998; 62:676-89.
40. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91:1310-6.
41. Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001; 114:3591-8.
42. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, et al. Cell cycle control of BRCA2. Cancer Res 1996; 56:4590-4.
43. Bertwistle D, Swift S, Marston NJ, Jackson LE, Crossland S, Crompton MR, et al. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res 1997; 57:5485-8.
44. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352:1337-9.
45. Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46:2884-8.
46. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993; 28:9-20.
47. Goss PE, Lesley MT. Hormones and cancer. In: Tannock IF, Hill RP, editors. The basic science of oncology, 3rd ed. New York: McGraw-Hill, 1998:263-94.
48. Osborne CK. Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 1992; 10:679-82.
49. Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S, De Luca LM. Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Exp Cell Res 1997; 234:293-9.
50. Murakoshi M, Nishino H, Satomi Y, Takayasu J, Hasegawa T, Tokuda H, et al. Potent preventive action of alpha-carotene against carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by alpha-carotene than beta-carotene. Cancer Res 1992; 53:6583-7.
51. Cottrell RC. Introduction: nutritional aspects of palm oil. Am J Clin Nutri 1991; 53: 939S-1009S.
52. Ng JH, Nesaretnam K, Reimann K, Lai LC. Effect of retinoic acid and palm oil carotenoids on oestrone sulphatase and oestradiol-17β hydroxysteroid dehydrogenase activities in MCF-7 and MDA-MB-231 breast cancer cell lines. Int J Cancer 2000; 88:135-8.
53. Newby JC, Johnston SR, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997; 3:1643-51.
54. Oehlet MK, Rehn M, Kristen P, Sutterlin M, Caffier H. Correlation of the EGF-receptor with cell kinetic and classical prognostic factors in breast cancer. Anticancer Res 1997; 173137-40.
55. Willsher PC, Pinder SE, Gee JM, Ellis IO, Chan SY, Nicholson RI, et al. c-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Res 1998; 18:3695-8.
56. Weidner N, Cady B, Goodson WH 3rd. Pathologic prognostic factors for patients with breast carcinoma. Which factors are important? Surg Oncol Clin N Am 1997; 6:415-62.
57. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995; 35:283-91.
58. Hartmann LC, Ingle JN, Wold LE, Farr GH Jr, Grill JP, Su IQ, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994; 74:2956-63.
59. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 2002;79:216-23.
60. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53 and efficacy of adjuvant therapy in lymph node positive breast cancer. J Natl Cancer Inst 1998; 90:1361-70.
61. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999; 79:1220-6.
62. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14:2702-8.
63. Leonard DS, Hill AD, Kelly L, Dijkstra B, McDermott E, O'Higgins NJ. Anti-human epidermal growth, factor receptor 2 monoclonal therapy for breast cancer. Br J Surg 2002; 89:262-71.
64. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
65. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20:3095-105.
66. Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol 1999; 10:1011-21.
67. Bergh J. Clinical studies of p53 in treatment and benefit of breast cancer patients. Endocr Relat Cancer 1999; 6:51-9.
68. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000; 11:647-63.
69. Wong SF, Reimann K, Lai LC. Effect of transforming growth factor-β1, insulin-like growth factor-I and insulin-like growth factor-II on cell growth and oestrogen metabolism in human breast cancer cell lines. Pathology 2001; 33: 454-9.
70. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid H, Derynck R, et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48:417-28.
71. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6:597-641.
72. Nilsen-Hamilton M. Transforming growth factor-β and its actions on cellular growth and differentiation. Curr Topic Dev Biol 1990; 24:95-136.
73. Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-β induction of type 1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 1987; 262:17467-74.
74. 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 1990; 61:777-85.
75. Dang CV. C-myc target genes involved in cell growth, apoptosis and metabolism. Mol Cell Biol 1999; 19:5913-22.
76. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, et al. Expression of transforming growth factor-alpha and its mRNA in human breast cancer: its regulation by oestrogen and its possible functional significance. Mol Endocrinol 1988; 2: 543-55.
77. Brunner N, Yee D, Kern FG, Spang-Thomsen M, Lippman ME, Cullen KJ. Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur J Cancer 1993; 29: 562-9.
78. Chrysogelos SA, Yarden RI, Lauber AH, Murphy JM. Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Res Treat 1994; 31:227-36.
79. Dupont J, Karas M, LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000; 275:35893-901.
80. Matsuda S, Kadowaki Y, Ichino M, Akiyama T, Toyoshima K, Yamamoto T. 17 Beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proc Natl Acad Sci USA 1993; 90:10803-7.
81. Migliaccio A, Pagano M, Auricchio F. Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 1993; 8:2183-91.
82. 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52:4261-4.
83. Lundholt BK, Briand P, Lykkesfeldt AE. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 2001; 67:199-214.
84. Aronica SM, Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 1993; 7:743-52.
85. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15:2174-83.
86. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH, et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 1995; 14:951-62.
87. Philips A, Chalbos D, Rochefort H. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 1993; 268:14103-8.
88. Musgrove EA, Hamilton JA, Lee CS, Sweenet KJ, Watts CK, Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993; 13:3577-87.
89. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-control led G1 checkpoint. Mol Cell Biol 1996; 16:6917-25.